MaRS Innovation’s (MI) projects and partnerships earned three separate article mentions in the December 2012 issue of Biotechnology Focus, including:
- MI and UHN’s partnership with Stem Cell Therapeutics was covered in the magazine’s Dealmakers subsection. Read the write-up on the Biotechnology Focus website.
- Cellax, a licensable technology that may produce a nanotechonology-based cancer drug, was highlighted in the magazine’s Business Corner section (read the write-up). Cellax is a joint project between MI and the Ontario Institute for Cancer Research.
- MaRS Innovation’s collaboration with the Centre for Commercialization of Regenerative Medicine was highlighted in a feature article, “Efforts to commercialize regenerative medicine in Canada growing steadily.”
Last November, the magazine also published Raphael Hofstein’s op-ed on how to build a strong biotechnology cluster from an academic base in the midst of a global recession.
Posted by Elizabeth Monier-Williams, marketing and communication manager.